SynthesisInternational journal of molecular sciences2022
miRNA-Mediated Epigenetic Regulation of Treatment Response in RA Patients-A Systematic Review.
Synthesis in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 11 citations in OpenAlex.
- Pathogenic Drivers of Difficult-to-Treat Rheumatoid Arthritis: Synovium and Beyond.International journal of molecular sciences · 2026Review
- Plasma miR-134-5p: a candidate biomarker for predicting non-response to anti-TNF therapy in rheumatoid arthritis.Frontiers in immunology · 2026Observational
- Threshold Effect of C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index on Disease Activity in Rheumatoid Arthritis: Unveiling a Nonlinear Association.Mediators of inflammation · 2026Article
- Baicalin improves the inflammatory response of RA-FLS by targeting the circ_0000734/miR-197-5p/IKBKB axis.Frontiers in immunology · 2026Article
- Analysis of epigenetic biomarkers for diagnosis and assessment of severity in rheumatoid arthritis: a cross-sectional study.Arthritis research & therapy · 2025Article
- Pharmacoepigenetic Biomarkers in Inflammatory Bowel Diseases: A Narrative Review.The Yale journal of biology and medicine · 2025Review
- Plasma levels of miR-21b and miR-146a can discriminate rheumatoid arthritis diagnosis and severity.BioMedicine · 2025Article
- Article
- Intestinal Dysbiosis, Tight Junction Proteins, and Inflammation in Rheumatoid Arthritis Patients: A Cross-Sectional Study.International journal of molecular sciences · 2024Article
- New Targets and Strategies for Rheumatoid Arthritis: From Signal Transduction to Epigenetic Aspect.Biomolecules · 2023Review
- Oxidative Stress and Epigenetics: miRNA Involvement in Rare Autoimmune Diseases.Antioxidants (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
This study aimed to evaluate the role of microRNAs (miRNA) as biomarkers of treatment response in rheumatoid arthritis (RA) patients through a systematic review of the literature. The MEDLINE and Embase databases were searched for studies including RA-diagnosed patients treated with disease-modifying antirheumatic drugs (DMARDs) that identify miRNAs as response predictors. Review inclusion criteria were met by 10 studies. The main outcome of the study was the response to treatment, defined according to EULAR criteria. A total of 839 RA patients and 67 healthy donors were included in the selected studies. RA patients presented seropositivity for the rheumatoid factor of 74.7% and anti-citrullinated C-peptide antibodies of 63.6%. After revision, 15 miRNAs were described as treatment response biomarkers for methotrexate, anti-tumour necrosis factor (TNF), and rituximab. Among treatments, methotrexate presented the highest number of predictor miRNAs: miR-16, miR-22, miR-132, miR-146a and miR-155. The most polyvalent miRNAs were miR-146a, predicting response to methotrexate and anti-TNF, and miR-125b, which predicts response to infliximab and rituximab. Our data support the role of miRNAs as biomarkers of treatment response in RA and point to DMARDs modifying the miRNAs expression. Nevertheless, further studies are needed since a meta-analysis that allows definitive conclusions is not possible due to the lack of studies in this field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.